1. Home
  2. ETON vs LAES Comparison

ETON vs LAES Comparison

Compare ETON & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • LAES
  • Stock Information
  • Founded
  • ETON 2017
  • LAES 2022
  • Country
  • ETON United States
  • LAES Switzerland
  • Employees
  • ETON N/A
  • LAES N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • LAES Semiconductors
  • Sector
  • ETON Health Care
  • LAES Technology
  • Exchange
  • ETON Nasdaq
  • LAES Nasdaq
  • Market Cap
  • ETON 428.5M
  • LAES 270.3M
  • IPO Year
  • ETON 2018
  • LAES N/A
  • Fundamental
  • Price
  • ETON $17.33
  • LAES $2.51
  • Analyst Decision
  • ETON Strong Buy
  • LAES Strong Buy
  • Analyst Count
  • ETON 3
  • LAES 1
  • Target Price
  • ETON $27.67
  • LAES $6.00
  • AVG Volume (30 Days)
  • ETON 221.4K
  • LAES 4.2M
  • Earning Date
  • ETON 05-13-2025
  • LAES 05-20-2025
  • Dividend Yield
  • ETON N/A
  • LAES N/A
  • EPS Growth
  • ETON N/A
  • LAES N/A
  • EPS
  • ETON N/A
  • LAES N/A
  • Revenue
  • ETON $39,011,000.00
  • LAES $10,981,000.00
  • Revenue This Year
  • ETON $92.33
  • LAES N/A
  • Revenue Next Year
  • ETON $52.62
  • LAES N/A
  • P/E Ratio
  • ETON N/A
  • LAES N/A
  • Revenue Growth
  • ETON 23.29
  • LAES N/A
  • 52 Week Low
  • ETON $3.18
  • LAES $0.29
  • 52 Week High
  • ETON $18.41
  • LAES $11.00
  • Technical
  • Relative Strength Index (RSI)
  • ETON 68.29
  • LAES 48.41
  • Support Level
  • ETON $16.43
  • LAES $2.18
  • Resistance Level
  • ETON $17.49
  • LAES $2.90
  • Average True Range (ATR)
  • ETON 0.88
  • LAES 0.19
  • MACD
  • ETON 0.19
  • LAES 0.01
  • Stochastic Oscillator
  • ETON 92.78
  • LAES 45.83

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: